Michael E Maniskas1,2,3,4, Jill M Roberts1,2,3, Rebecca Trueman5, Annastazia E Learoyd5, Amanda Gorman2,3, Justin F Fraser1,3,4,6,7, Gregory J Bix1,2,3,4,6. 1. Department of Anatomy & Neurobiology, University of Kentucky, Lexington, Kentucky, USA. 2. Sanders Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA. 3. Center for Advanced Translational Stroke Science, University of Kentucky, Lexington, Kentucky, USA. 4. Department of Neurosurgery, University of Kentucky, Lexington, Kentucky, USA. 5. School of Life Sciences, University of Nottingham, Nottingham, UK. 6. Department of Neurology, University of Kentucky, Lexington, Kentucky, USA. 7. Department of Radiology, University of Kentucky, Lexington, Kentucky, USA.
Abstract
BACKGROUND: Nitroglycerin (also known as glyceryl trinitrate (GTN)), a vasodilator best known for treatment of ischemic heart disease, has also been investigated for its potential therapeutic benefit in ischemic stroke. The completed Efficacy of Nitric Oxide in Stroke trial suggested that GTN has therapeutic benefit with acute (within 6 hours) transdermal systemic sustained release therapy. OBJECTIVE: To examine an alternative use of GTN as an acute therapy for ischemic stroke following successful recanalization. METHODS: We administered GTN IA following transient middle cerebral artery occlusion in mice. Because no standard dose of GTN is available following emergent large vessel occlusion, we performed a dose-response (3.12, 6.25, 12.5, and 25 µg/µL) analysis. Next, we looked at blood perfusion (flow) through the middle cerebral artery using laser Doppler flowmetry. Functional outcomes, including forced motor movement rotor rod, were assessed in the 3.12, 6.25, and 12.5 µg/µL groups. Histological analysis was performed using cresyl violet for infarct volume, and glial fibrillary activating protein (GFAP) and NeuN immunohistochemistry for astrocyte activation and mature neuron survival, respectively. RESULTS: Overall, we found that acute post-stroke IA GTN had little effect on vessel dilatation after 15 min. Functional analysis showed a significant difference between GTN (3.12 and 6.25 µg/µL) and control at post-stroke day 1. Histological measures showed a significant reduction in infarct volume and GFAP immunoreactivity and a significant increase in NeuN. CONCLUSIONS: These results demonstrate that acute IA GTN is neuroprotective in experimental ischemic stroke and warrants further study as a potentially new stroke therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND:Nitroglycerin (also known as glyceryl trinitrate (GTN)), a vasodilator best known for treatment of ischemic heart disease, has also been investigated for its potential therapeutic benefit in ischemic stroke. The completed Efficacy of Nitric Oxide in Stroke trial suggested that GTN has therapeutic benefit with acute (within 6 hours) transdermal systemic sustained release therapy. OBJECTIVE: To examine an alternative use of GTN as an acute therapy for ischemic stroke following successful recanalization. METHODS: We administered GTN IA following transient middle cerebral artery occlusion in mice. Because no standard dose of GTN is available following emergent large vessel occlusion, we performed a dose-response (3.12, 6.25, 12.5, and 25 µg/µL) analysis. Next, we looked at blood perfusion (flow) through the middle cerebral artery using laser Doppler flowmetry. Functional outcomes, including forced motor movement rotor rod, were assessed in the 3.12, 6.25, and 12.5 µg/µL groups. Histological analysis was performed using cresyl violet for infarct volume, and glial fibrillary activating protein (GFAP) and NeuN immunohistochemistry for astrocyte activation and mature neuron survival, respectively. RESULTS: Overall, we found that acute post-stroke IA GTN had little effect on vessel dilatation after 15 min. Functional analysis showed a significant difference between GTN (3.12 and 6.25 µg/µL) and control at post-stroke day 1. Histological measures showed a significant reduction in infarct volume and GFAP immunoreactivity and a significant increase in NeuN. CONCLUSIONS: These results demonstrate that acute IA GTN is neuroprotective in experimental ischemic stroke and warrants further study as a potentially new stroke therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Boyeon Lee; Douglas Clarke; Abraham Al Ahmad; Michael Kahle; Christi Parham; Lisa Auckland; Courtney Shaw; Mehmet Fidanboylu; Anthony Wayne Orr; Omolara Ogunshola; Andrzej Fertala; Sarah A Thomas; Gregory J Bix Journal: J Clin Invest Date: 2011-07-11 Impact factor: 14.808
Authors: Jeffrey L Saver; Reza Jahan; Elad I Levy; Tudor G Jovin; Blaise Baxter; Raul G Nogueira; Wayne Clark; Ronald Budzik; Osama O Zaidat Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Lisa Woodhouse; Polly Scutt; Kailash Krishnan; Eivind Berge; John Gommans; George Ntaios; Joanna Wardlaw; Nikola Sprigg; Philip M Bath Journal: Stroke Date: 2015-10-13 Impact factor: 7.914
Authors: Philip M W Bath; Katie Robson; Lisa J Woodhouse; Nikola Sprigg; Robert Dineen; Stuart Pocock Journal: Int J Stroke Date: 2014-12-30 Impact factor: 5.266
Authors: Valery L Feigin; Mohammad H Forouzanfar; Rita Krishnamurthi; George A Mensah; Myles Connor; Derrick A Bennett; Andrew E Moran; Ralph L Sacco; Laurie Anderson; Thomas Truelsen; Martin O'Donnell; Narayanaswamy Venketasubramanian; Suzanne Barker-Collo; Carlene M M Lawes; Wenzhi Wang; Yukito Shinohara; Emma Witt; Majid Ezzati; Mohsen Naghavi; Christopher Murray Journal: Lancet Date: 2014-01-18 Impact factor: 79.321
Authors: Philip M W Bath; Aimee Houlton; Lisa Woodhouse; Nikola Sprigg; Joanna Wardlaw; Stuart Pocock Journal: Int J Stroke Date: 2014-03-03 Impact factor: 5.266
Authors: Sherief Ghozy; Abdullah Reda; Joseph Varney; Ahmed Sallam Elhawary; Jaffer Shah; Kimberly Murry; Mohamed Gomaa Sobeeh; Sandeep S Nayak; Ahmed Y Azzam; Waleed Brinjikji; Ramanathan Kadirvel; David F Kallmes Journal: Front Neurol Date: 2022-05-31 Impact factor: 4.086
Authors: Kathleen E Salmeron; Michael E Maniskas; Danielle N Edwards; Raymond Wong; Ivana Rajkovic; Amanda Trout; Abir A Rahman; Samantha Hamilton; Justin F Fraser; Emmanuel Pinteaux; Gregory J Bix Journal: J Neuroinflammation Date: 2019-11-14 Impact factor: 8.322
Authors: Annabel J Sorby-Adams; Annastazia E Learoyd; Philip M Bath; Fiona Burrows; Tracy D Farr; Anna V Leonard; Ingo Schiessl; Stuart M Allan; Renée J Turner; Rebecca C Trueman Journal: J Cereb Blood Flow Metab Date: 2021-05-26 Impact factor: 6.200